Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe

Amélie Menard¹, Clementine Montagnac, Caroline Solas, Line Meddeb, Catherine Dhiver, Christelle Tomei, Isabelle Ravaux, Herve Tissot-Dupont, Saadia Mokhtari, Philippe Colson, Andreas Stein

Affiliations

Affiliation

¹ aURMITE, UM63, CNRS 7278, IRD 198, IHU-Méditerranée Infection bLaboratoire de Pharmacocinétique et Toxicologie, INSERM UMR 911-CRO2-SMARTc, AP-HM Timone, Aix-Marseille University, Marseille, France.

PMID: 28441180
DOI: 10.1097/QAD.0000000000001459

Comment

Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe

Amélie Menard et al. AIDS. 2017.

. 2017 May 15;31(8):1201-1203.

doi: 10.1097/QAD.0000000000001459.

Authors

Amélie Menard¹, Clementine Montagnac, Caroline Solas, Line Meddeb, Catherine Dhiver, Christelle Tomei, Isabelle Ravaux, Herve Tissot-Dupont, Saadia Mokhtari, Philippe Colson, Andreas Stein

Affiliation

¹ aURMITE, UM63, CNRS 7278, IRD 198, IHU-Méditerranée Infection bLaboratoire de Pharmacocinétique et Toxicologie, INSERM UMR 911-CRO2-SMARTc, AP-HM Timone, Aix-Marseille University, Marseille, France.

PMID: 28441180
DOI: 10.1097/QAD.0000000000001459

No abstract available

PubMed Disclaimer

Comment in

Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect.
Kheloufi F, Boucherie Q, Blin O, Micallef J. Kheloufi F, et al. AIDS. 2017 Jul 31;31(12):1775-1777. doi: 10.1097/QAD.0000000000001557. AIDS. 2017. PMID: 28700395 No abstract available.
Dolutegravir and neuropsychiatric adverse events: a continuing debate.
Cailhol J, Rouyer C, Alloui C, Jeantils V. Cailhol J, et al. AIDS. 2017 Sep 10;31(14):2023-2024. doi: 10.1097/QAD.0000000000001596. AIDS. 2017. PMID: 28857781 No abstract available.

Comment on

Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.
Bonfanti P, Madeddu G, Gulminetti R, Squillace N, Orofino G, Vitiello P, Rusconi S, Celesia BM, Maggi P, Ricci E; CISAI Study group. Bonfanti P, et al. AIDS. 2017 Jan 28;31(3):455-457. doi: 10.1097/QAD.0000000000001351. AIDS. 2017. PMID: 28079544 No abstract available.
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients.
Borghetti A, Baldin G, Capetti A, Sterrantino G, Rusconi S, Latini A, Giacometti A, Madeddu G, Picarelli C, De Marco R, Cossu MV, Lagi F, Cauda R, De Luca A, Di Giambenedetto S; Odoacre Study Group. Borghetti A, et al. AIDS. 2017 Jan 28;31(3):457-459. doi: 10.1097/QAD.0000000000001357. AIDS. 2017. PMID: 28079545 No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe

Affiliation

Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe

Authors

Affiliation

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical